N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.

doi:10.1023/b:pham.0000016246.84974.ec

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis.

Pharmaceutical research - 1 Feb 2004

Kumagai Shunichi, Komada Fusao, Kita Tomoko, Morinobu Akio, Ozaki Shoichi, Ishida Hiroshi, Sano Hajime, Matsubara Tsukasa, Okumura Katsuhiko

Abstract excerpt

PURPOSE: For the individual optimization of drug therapy with sulfasalazine (SASP), we studied the influence of the N-acetyltransferase 2 (NAT2) genotype on the pharmacokinetics, efficacy, and incidence of adverse reactions of SASP in patients. METHODS: Ninety-six rheumatoid arthritis (RA) patients were treated or had been treated with 0.5 and/or 1.0 g/day of SASP. The wild-type allele (NAT2*4) and three variant...

Topics

Antirheumatic Agents
Arthritis, Rheumatoid
Arylamine N-Acetyltransferase
Female
Genotype
Humans
Male
Middle Aged
Sulfasalazine
Time Factors

Source

Open in PubMed

Identifiers

PMID: 15032315
DOI: 10.1023/b:pham.0000016246.84974.ec

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics